Creative Medical Technology Holdings, Inc. Financing Receivable, after Allowance for Credit Loss
Creative Medical Technology Holdings, Inc. (CELZ) had Financing Receivable, after Allowance for Credit Loss of $109.34 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets
us-gaap:NotesReceivableNet · last filed 2026-08-07
- 2026-06-30: Financing Receivable, after Allowance for Credit Loss $109.34K.
- 2026-03-31: Financing Receivable, after Allowance for Credit Loss $105.71K.
- 2025-12-31: Financing Receivable, after Allowance for Credit Loss $52.08K.
- 2024-12-31: Financing Receivable, after Allowance for Credit Loss $0.00.
| Period end | Financing Receivable, after Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $109.34K 10-Q · filed 2026-08-07 |
| 2026-03-31 | $105.71K 10-Q · filed 2026-05-08 |
| 2025-12-31 | $52.08K 10-Q · filed 2026-08-07 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |